

## **OCR emerges as a leading vet CRO in Europe after signing a succession of major contracts**

**Lille, 26<sup>th</sup> October 2015** – OCR has reinforced its position as a leading vet CRO after the signature of three significant full service contracts. Innovators Beta Innov, Atlanthera and an undisclosed leader in the vet pharmaceutical industry, have all recently entrusted OCR with innovative comparative medicine studies across a range of pathologies, further validating the company's offering in parallel oncology research.

Beta Innov aims to develop a treatment using their BIM2b molecule for glioblastoma, an aggressive fast-growing malignant brain tumour. The innovative pharmaceutical R&D company chose OCR because of their knowledge of this complex condition and their ability to manage the major medical and technical challenges presented by the study. Several investigation centres equipped with the latest technologies will collaborate to ensure the recruitment of pertinent patients, using an IRM scan for diagnosis. Glioblastoma represents a major unmet medical need in humans and it is envisaged that this initial study, designed by OCR, will pave the way for additional clinical studies to advance innovative therapies, such as a combination approach with radiotherapy, for the challenging disease.

Atlanthera has developed a novel treatment that specifically targets bone cancers. OCR's role in the study will be to determine the recommended dose and carry-out efficacy studies on the 12b80 product in dogs with spontaneous non-operable tumours in advance of progressing to studies in humans. This project highlights yet again the importance of comparative oncology studies as canine bone tumours are an excellent model for advancing new drug candidates.

Finally, a major undisclosed vet player has selected OCR for an important pivotal study in a new drug application for animal oncology in advance of its marketing authorisation. With over 110 patients across 25 centres, OCR will be responsible for all aspects of the programme including protocol design, data management, biostatistics, pharmacovigilance, study monitoring and final reporting. This contract confirms OCR's ability to design, conduct and manage all phases of key clinical studies.

Mr. Matthieu Dubruque, COO of OCR, commented on both the scientific and business value of these projects, “The succession of these major service contracts, each individually of immense scientific interest, confirms OCR’s position and reputation as a leading full vet contract research organisation. The quantity of new studies undertaken by the company and multiple approaches from the pharmaceutical sector highlight the need for highly predictive animal models of human diseases and underline the growing interest in our offer from the vet oncology sector. Moreover, these developments are all in line with our business and research objectives for 2015.”

**About OCR:**

Founded in 2011 by Dr. Dominique Tierny, OCR is a CRO based in Eurasanté, Lille, France and employs 15 people. Unique in Europe, OCR aims to accelerate the development of new human and pet treatments for serious chronic diseases by addressing the unmet need of providing access to highly predictive models via their ethical clinical studies in pets. OCR works with pharmaceutical partners for the cost-effective design and management of in vitro, pre-clinical and clinical trials in dogs and cats. This innovative approach helps to advance the R&D process for new drug candidates and medical devices for humans in a variety of therapeutic areas including oncology, cardiology, neurology and inflammation. OCR has already signed partnerships with leading players in the veterinary and pharmaceutical sectors such as Pierre Fabre, Beta Innov, Ecrins Therapeutics and Merial.

To learn more about OCR: [www.oncovet-clinical-research.com](http://www.oncovet-clinical-research.com)

To learn more about Beta Innov: [www.beta-innov.com](http://www.beta-innov.com)

To learn more about Atlathera: [www.atlanthera.com](http://www.atlanthera.com)

**Media:**

Matthieu Dubruque – COO [mdubruque@oncovet-clinical-research.com](mailto:mdubruque@oncovet-clinical-research.com)

+33 (0) 663 513 971